| Bacillus subtilis |
4'-phosphopantetheinyl transferase ffp |
Potency |
56234.1 |
nM |
None |
| Canis lupus familiaris |
Canis familiaris |
CL |
1.9 |
mL.min-1.kg-1 |
10.1021/jm991030j |
| Canis lupus familiaris |
Canis familiaris |
Clearance |
0.2 |
ul min-1 |
10.1021/jm991030j |
| Homo sapiens |
A-375 |
IC50 |
67360.0 |
nM |
10.1021/acs.jmedchem.1c00582 |
| Homo sapiens |
Adenosine A1 receptor |
AC50 |
30000.0 |
nM |
10.1038/s41467-023-40064-9 |
| Homo sapiens |
Adenosine A2a receptor |
AC50 |
30000.0 |
nM |
10.1038/s41467-023-40064-9 |
| Homo sapiens |
Adenosine A3 receptor |
AC50 |
30000.0 |
nM |
10.1038/s41467-023-40064-9 |
| Homo sapiens |
Alpha-1a adrenergic receptor |
AC50 |
10000.0 |
nM |
10.1038/s41467-023-40064-9 |
| Homo sapiens |
Alpha-1a adrenergic receptor |
AC50 |
30000.0 |
nM |
10.1038/s41467-023-40064-9 |
| Homo sapiens |
Alpha-2a adrenergic receptor |
AC50 |
10000.0 |
nM |
10.1038/s41467-023-40064-9 |
| Homo sapiens |
Alpha-2b adrenergic receptor |
AC50 |
10000.0 |
nM |
10.1038/s41467-023-40064-9 |
| Homo sapiens |
Alpha-2c adrenergic receptor |
AC50 |
10000.0 |
nM |
10.1038/s41467-023-40064-9 |
| Homo sapiens |
Beta-1 adrenergic receptor |
AC50 |
30000.0 |
nM |
10.1038/s41467-023-40064-9 |
| Homo sapiens |
Beta-2 adrenergic receptor |
AC50 |
10000.0 |
nM |
10.1038/s41467-023-40064-9 |
| Homo sapiens |
Beta-2 adrenergic receptor |
AC50 |
30000.0 |
nM |
10.1038/s41467-023-40064-9 |
| Homo sapiens |
Beta-3 adrenergic receptor |
AC50 |
30000.0 |
nM |
10.1038/s41467-023-40064-9 |
| Homo sapiens |
Bile acid receptor FXR |
AC50 |
30000.0 |
nM |
10.1038/s41467-023-40064-9 |
| Homo sapiens |
Bile acid transporter |
IC50 |
30000000.0 |
nM |
10.1016/j.bmcl.2019.126623 |
| Homo sapiens |
Bile salt export pump |
AC50 |
17999.9 |
nM |
10.1038/s41467-023-40064-9 |
| Homo sapiens |
Bile salt export pump |
IC50 |
22000.0 |
nM |
10.1093/toxsci/kfq269 |
| Homo sapiens |
Bile salt export pump |
IC50 |
23000.0 |
nM |
10.1093/toxsci/kft176 |
| Homo sapiens |
Bile salt export pump |
IC50 |
25300.0 |
nM |
10.1124/dmd.112.047068 |
| Homo sapiens |
Bile salt export pump |
IC50 |
29000.0 |
nM |
10.1002/hep.27206 |
| Homo sapiens |
Bile salt export pump |
IC50 |
38100.0 |
nM |
10.1124/dmd.111.040758 |
| Homo sapiens |
Bradykinin B1 receptor |
AC50 |
30000.0 |
nM |
10.1038/s41467-023-40064-9 |
| Homo sapiens |
Bradykinin B2 receptor |
AC50 |
30000.0 |
nM |
10.1038/s41467-023-40064-9 |
| Homo sapiens |
Caco-2 |
logPapp |
-5.98 |
None |
10.1016/j.bmc.2009.08.022 |
| Homo sapiens |
Caco-2 |
logPapp |
-5.98 |
None |
10.1016/j.bmc.2011.03.011 |
| Homo sapiens |
Canalicular multispecific organic anion transporter 1 |
Activity |
nan |
None |
10.1093/toxsci/kft176 |
| Homo sapiens |
Canalicular multispecific organic anion transporter 1 |
Inhibition |
nan |
% |
10.1093/toxsci/kft176 |
| Homo sapiens |
Canalicular multispecific organic anion transporter 2 |
IC50 |
42000.0 |
nM |
10.1093/toxsci/kft176 |
| Homo sapiens |
Cannabinoid CB1 receptor |
AC50 |
10000.0 |
nM |
10.1038/s41467-023-40064-9 |
| Homo sapiens |
Cannabinoid CB1 receptor |
AC50 |
30000.0 |
nM |
10.1038/s41467-023-40064-9 |
| Homo sapiens |
Cholecystokinin A receptor |
AC50 |
30000.0 |
nM |
10.1038/s41467-023-40064-9 |
| Homo sapiens |
Cholecystokinin B receptor |
AC50 |
30000.0 |
nM |
10.1038/s41467-023-40064-9 |
| Homo sapiens |
Corticotropin releasing factor receptor 1 |
AC50 |
30000.0 |
nM |
10.1038/s41467-023-40064-9 |
| Homo sapiens |
Corticotropin releasing factor receptor 2 |
AC50 |
30000.0 |
nM |
10.1038/s41467-023-40064-9 |
| Homo sapiens |
Cyclooxygenase-2 |
AC50 |
30000.0 |
nM |
10.1038/s41467-023-40064-9 |
| Homo sapiens |
Cytochrome P450 2C9 |
Drug metabolism |
nan |
None |
10.1016/j.ejmech.2016.06.006 |
| Homo sapiens |
Cytochrome P450 2C9 |
FC |
1.0 |
None |
10.1016/j.bmcl.2016.06.088 |
| Homo sapiens |
Cytochrome P450 2C9 |
Stability |
75.8 |
% |
10.1016/j.ejmech.2016.06.006 |
| Homo sapiens |
Cytochrome P450 2D6 |
FC |
1.0 |
None |
10.1016/j.bmcl.2016.06.088 |
| Homo sapiens |
Cytochrome P450 2D6 |
Stability |
99.0 |
% |
10.1016/j.ejmech.2016.06.006 |
| Homo sapiens |
Cytochrome P450 3A |
Activity |
69.0 |
% |
10.1021/acs.jmedchem.0c02245 |
| Homo sapiens |
Cytochrome P450 3A4 |
Activity |
nan |
None |
None |
| Homo sapiens |
Cytochrome P450 3A4 |
Drug metabolism |
nan |
None |
10.1016/j.ejmech.2016.06.006 |
| Homo sapiens |
Cytochrome P450 3A4 |
FC |
1.0 |
None |
10.1016/j.bmcl.2016.06.088 |
| Homo sapiens |
Cytochrome P450 3A4 |
Stability |
20.9 |
% |
10.1016/j.ejmech.2016.06.006 |
| Homo sapiens |
Delta opioid receptor |
AC50 |
30000.0 |
nM |
10.1038/s41467-023-40064-9 |
| Homo sapiens |
Deoxyhypusine synthase |
IC50 |
60830.0 |
nM |
10.1021/acs.jmedchem.1c00582 |
| Homo sapiens |
Dopamine D1 receptor |
AC50 |
10000.0 |
nM |
10.1038/s41467-023-40064-9 |
| Homo sapiens |
Dopamine D2 receptor |
AC50 |
10000.0 |
nM |
10.1038/s41467-023-40064-9 |
| Homo sapiens |
Dopamine D3 receptor |
AC50 |
30000.0 |
nM |
10.1038/s41467-023-40064-9 |
| Homo sapiens |
Dopamine transporter |
AC50 |
30000.0 |
nM |
10.1038/s41467-023-40064-9 |
| Homo sapiens |
Endothelin receptor ET-A |
AC50 |
28.6 |
nM |
10.1038/s41467-023-40064-9 |
| Homo sapiens |
Endothelin receptor ET-A |
IC50 |
4.7 |
nM |
10.1016/j.ejmech.2016.06.006 |
| Homo sapiens |
Endothelin receptor ET-A |
IC50 |
8.0 |
nM |
10.1016/S0960-894X(97)00400-9 |
| Homo sapiens |
Endothelin receptor ET-A |
IC50 |
8.4 |
nM |
10.1039/C5MD00169B |
| Homo sapiens |
Endothelin receptor ET-A |
IC50 |
8.9 |
nM |
10.1016/j.bmc.2012.06.011 |
| Homo sapiens |
Endothelin receptor ET-A |
IC50 |
40.0 |
nM |
10.1016/s0960-894x(02)01084-3 |
| Homo sapiens |
Endothelin receptor ET-A |
IC50 |
45.0 |
nM |
10.1016/j.bmcl.2016.06.014 |
| Homo sapiens |
Endothelin receptor ET-A |
IC50 |
45.0 |
nM |
10.1021/acs.jmedchem.5b01781 |
| Homo sapiens |
Endothelin receptor ET-A |
IC50 |
45.0 |
nM |
10.1021/jm3009103 |
| Homo sapiens |
Endothelin receptor ET-A |
IC50 |
80.0 |
nM |
10.1016/j.bmcl.2016.06.014 |
| Homo sapiens |
Endothelin receptor ET-A |
IC50 |
80.0 |
nM |
10.1016/S0960-894X(97)00400-9 |
| Homo sapiens |
Endothelin receptor ET-A |
IC50 |
80.0 |
nM |
10.1021/acs.jmedchem.0c01093 |
| Homo sapiens |
Endothelin receptor ET-A |
IC50 |
1584.89 |
nM |
10.1021/acs.jmedchem.8b00435 |
| Homo sapiens |
Endothelin receptor ET-A |
IC50 |
nan |
nM |
10.1021/jm030528p |
| Homo sapiens |
Endothelin receptor ET-A |
Ki |
6.5 |
nM |
10.1021/jm970101g |
| Homo sapiens |
Endothelin receptor ET-A |
Ki |
8.0 |
nM |
10.1021/jm020289q |
| Homo sapiens |
Endothelin receptor ET-A |
pKb |
8.01 |
None |
10.1021/acs.jmedchem.8b00435 |
| Homo sapiens |
Endothelin receptor ET-A |
T1/2 |
0.01667 |
hr |
10.1021/acs.jmedchem.5b01781 |
| Homo sapiens |
Endothelin receptor ET-B |
AC50 |
270.5 |
nM |
10.1038/s41467-023-40064-9 |
| Homo sapiens |
Endothelin receptor ET-B |
IC50 |
95.0 |
nM |
10.1016/j.ejmech.2016.06.006 |
| Homo sapiens |
Endothelin receptor ET-B |
IC50 |
150.0 |
nM |
10.1016/j.bmcl.2016.06.014 |
| Homo sapiens |
Endothelin receptor ET-B |
IC50 |
150.0 |
nM |
10.1016/S0960-894X(97)00400-9 |
| Homo sapiens |
Endothelin receptor ET-B |
IC50 |
202.0 |
nM |
10.1016/j.bmcl.2016.06.014 |
| Homo sapiens |
Endothelin receptor ET-B |
IC50 |
202.0 |
nM |
10.1021/acs.jmedchem.5b01781 |
| Homo sapiens |
Endothelin receptor ET-B |
IC50 |
202.0 |
nM |
10.1021/jm3009103 |
| Homo sapiens |
Endothelin receptor ET-B |
IC50 |
280.0 |
nM |
10.1016/s0960-894x(02)01084-3 |
| Homo sapiens |
Endothelin receptor ET-B |
IC50 |
1000.0 |
nM |
10.1021/acs.jmedchem.8b00435 |
| Homo sapiens |
Endothelin receptor ET-B |
Ki |
80.0 |
nM |
10.1021/jm020289q |
| Homo sapiens |
Endothelin receptor ET-B |
Ki |
340.0 |
nM |
10.1021/jm970101g |
| Homo sapiens |
Endothelin receptor ET-B |
pKb |
6.15 |
None |
10.1021/acs.jmedchem.8b00435 |
| Homo sapiens |
Equilibrative nucleoside transporter 1 |
AC50 |
30000.0 |
nM |
10.1038/s41467-023-40064-9 |
| Homo sapiens |
Estrogen receptor alpha |
AC50 |
30000.0 |
nM |
10.1038/s41467-023-40064-9 |
| Homo sapiens |
Estrogen receptor beta |
AC50 |
30000.0 |
nM |
10.1038/s41467-023-40064-9 |
| Homo sapiens |
GABA-B receptor 1 |
AC50 |
10000.0 |
nM |
10.1038/s41467-023-40064-9 |
| Homo sapiens |
Gastric inhibitory polypeptide receptor |
AC50 |
30000.0 |
nM |
10.1038/s41467-023-40064-9 |
| Homo sapiens |
Ghrelin receptor |
AC50 |
30000.0 |
nM |
10.1038/s41467-023-40064-9 |
| Homo sapiens |
Glucagon receptor |
AC50 |
30000.0 |
nM |
10.1038/s41467-023-40064-9 |
| Homo sapiens |
Glucocorticoid receptor |
AC50 |
30000.0 |
nM |
10.1038/s41467-023-40064-9 |
| Homo sapiens |
HERG |
AC50 |
30000.0 |
nM |
10.1038/s41467-023-40064-9 |
| Homo sapiens |
Histamine H1 receptor |
AC50 |
10000.0 |
nM |
10.1038/s41467-023-40064-9 |
| Homo sapiens |
Histamine H1 receptor |
AC50 |
30000.0 |
nM |
10.1038/s41467-023-40064-9 |
| Homo sapiens |
Histamine H2 receptor |
AC50 |
10000.0 |
nM |
10.1038/s41467-023-40064-9 |
| Homo sapiens |
Histamine H3 receptor |
AC50 |
10000.0 |
nM |
10.1038/s41467-023-40064-9 |
| Homo sapiens |
Histone deacetylase 6 |
Inhibition |
-7.67 |
% |
10.6019/CHEMBL4808148 |
| Homo sapiens |
Histone deacetylase 6 |
Inhibition |
22.48 |
% |
10.6019/CHEMBL4808148 |
| Homo sapiens |
Homo sapiens |
Activity |
nan |
None |
10.1002/hep.27206 |
| Homo sapiens |
Homo sapiens |
AUC |
8914.34 |
ng.hr.mL-1 |
10.1093/toxsci/kft176 |
| Homo sapiens |
Homo sapiens |
CL |
3.7 |
mL.min-1.kg-1 |
10.1021/jm991030j |
| Homo sapiens |
Homo sapiens |
Clearance |
0.2 |
ul min-1 |
10.1021/jm991030j |
| Homo sapiens |
Homo sapiens |
Cmax |
7433.0 |
nM |
10.1002/hep.27206 |
| Homo sapiens |
Homo sapiens |
Css |
1.347 |
uM |
10.1093/toxsci/kft176 |
| Homo sapiens |
Homo sapiens |
DILI_Concern |
nan |
None |
10.1016/j.drudis.2016.02.015 |
| Homo sapiens |
Homo sapiens |
DILI_severity_class |
7.0 |
None |
10.1016/j.drudis.2016.02.015 |
| Homo sapiens |
Homo sapiens |
F |
50.0 |
% |
10.1016/j.bmc.2007.08.060 |
| Homo sapiens |
Homo sapiens |
Pc |
nan |
None |
10.1021/jm020289q |
| Homo sapiens |
Kappa opioid receptor |
AC50 |
10000.0 |
nM |
10.1038/s41467-023-40064-9 |
| Homo sapiens |
LXR-alpha |
AC50 |
7799.9 |
nM |
10.1038/s41467-023-40064-9 |
| Homo sapiens |
LXR-alpha |
AC50 |
30000.0 |
nM |
10.1038/s41467-023-40064-9 |
| Homo sapiens |
LXR-beta |
AC50 |
30000.0 |
nM |
10.1038/s41467-023-40064-9 |
| Homo sapiens |
Melanocortin receptor 3 |
AC50 |
30000.0 |
nM |
10.1038/s41467-023-40064-9 |
| Homo sapiens |
Melanocortin receptor 4 |
AC50 |
30000.0 |
nM |
10.1038/s41467-023-40064-9 |
| Homo sapiens |
Monoamine oxidase A |
AC50 |
10000.0 |
nM |
10.1038/s41467-023-40064-9 |
| Homo sapiens |
Motilin receptor |
AC50 |
10000.0 |
nM |
10.1038/s41467-023-40064-9 |
| Homo sapiens |
Multidrug resistance-associated protein 4 |
IC50 |
22000.0 |
nM |
10.1093/toxsci/kft176 |
| Homo sapiens |
Mu opioid receptor |
AC50 |
30000.0 |
nM |
10.1038/s41467-023-40064-9 |
| Homo sapiens |
Muscarinic acetylcholine receptor M1 |
AC50 |
10000.0 |
nM |
10.1038/s41467-023-40064-9 |
| Homo sapiens |
Muscarinic acetylcholine receptor M2 |
AC50 |
10000.0 |
nM |
10.1038/s41467-023-40064-9 |
| Homo sapiens |
Muscarinic acetylcholine receptor M3 |
AC50 |
30000.0 |
nM |
10.1038/s41467-023-40064-9 |
| Homo sapiens |
Neuronal acetylcholine receptor protein alpha-4 subunit |
AC50 |
30000.0 |
nM |
10.1038/s41467-023-40064-9 |
| Homo sapiens |
Neuropeptide Y receptor type 1 |
AC50 |
30000.0 |
nM |
10.1038/s41467-023-40064-9 |
| Homo sapiens |
Neuropeptide Y receptor type 2 |
AC50 |
30000.0 |
nM |
10.1038/s41467-023-40064-9 |
| Homo sapiens |
Neurotensin receptor 1 |
AC50 |
30000.0 |
nM |
10.1038/s41467-023-40064-9 |
| Homo sapiens |
Norepinephrine transporter |
AC50 |
30000.0 |
nM |
10.1038/s41467-023-40064-9 |
| Homo sapiens |
Nuclear receptor subfamily 1 group I member 3 |
AC50 |
2100.0 |
nM |
10.1038/s41467-023-40064-9 |
| Homo sapiens |
Peroxisome proliferator-activated receptor alpha |
AC50 |
30000.0 |
nM |
10.1038/s41467-023-40064-9 |
| Homo sapiens |
Phosphodiesterase 3A |
AC50 |
30000.0 |
nM |
10.1038/s41467-023-40064-9 |
| Homo sapiens |
Phosphodiesterase 4D |
AC50 |
30000.0 |
nM |
10.1038/s41467-023-40064-9 |
| Homo sapiens |
Plasma |
fCmax |
0.149 |
uM |
10.1124/dmd.111.040758 |
| Homo sapiens |
Pregnane X receptor |
AC50 |
8000.0 |
nM |
10.1038/s41467-023-40064-9 |
| Homo sapiens |
Pregnane X receptor |
AC50 |
30000.0 |
nM |
10.1038/s41467-023-40064-9 |
| Homo sapiens |
Pregnane X receptor |
EC50 |
8900.0 |
nM |
10.1124/dmd.110.035105 |
| Homo sapiens |
Pregnane X receptor |
EC50 |
12600.0 |
nM |
10.1124/dmd.110.035105 |
| Homo sapiens |
Pregnane X receptor |
EC50 |
14100.0 |
nM |
10.1124/dmd.110.035105 |
| Homo sapiens |
Pregnane X receptor |
Efficacy |
71.5 |
% |
10.1124/dmd.110.035105 |
| Homo sapiens |
Pregnane X receptor |
Efficacy |
82.8 |
% |
10.1124/dmd.110.035105 |
| Homo sapiens |
Pregnane X receptor |
Efficacy |
163.5 |
% |
10.1124/dmd.110.035105 |
| Homo sapiens |
Progesterone receptor |
AC50 |
30000.0 |
nM |
10.1038/s41467-023-40064-9 |
| Homo sapiens |
Retinoic acid receptor alpha |
AC50 |
30000.0 |
nM |
10.1038/s41467-023-40064-9 |
| Homo sapiens |
Retinoic acid receptor beta |
AC50 |
30000.0 |
nM |
10.1038/s41467-023-40064-9 |
| Homo sapiens |
Retinoic acid receptor gamma |
AC50 |
30000.0 |
nM |
10.1038/s41467-023-40064-9 |
| Homo sapiens |
Serotonin 1a (5-HT1a) receptor |
AC50 |
10000.0 |
nM |
10.1038/s41467-023-40064-9 |
| Homo sapiens |
Serotonin 2a (5-HT2a) receptor |
AC50 |
10000.0 |
nM |
10.1038/s41467-023-40064-9 |
| Homo sapiens |
Serotonin 2a (5-HT2a) receptor |
AC50 |
30000.0 |
nM |
10.1038/s41467-023-40064-9 |
| Homo sapiens |
Serotonin 2b (5-HT2b) receptor |
AC50 |
10000.0 |
nM |
10.1038/s41467-023-40064-9 |
| Homo sapiens |
Serotonin 2c (5-HT2c) receptor |
AC50 |
30000.0 |
nM |
10.1038/s41467-023-40064-9 |
| Homo sapiens |
Serotonin 3a (5-HT3a) receptor |
AC50 |
30000.0 |
nM |
10.1038/s41467-023-40064-9 |
| Homo sapiens |
Serotonin transporter |
AC50 |
30000.0 |
nM |
10.1038/s41467-023-40064-9 |
| Homo sapiens |
SK-MEL-28 |
IC50 |
53650.0 |
nM |
10.1021/acs.jmedchem.1c00582 |
| Homo sapiens |
Thromboxane A2 receptor |
AC50 |
30000.0 |
nM |
10.1038/s41467-023-40064-9 |
| Homo sapiens |
Type-1 angiotensin II receptor |
AC50 |
30000.0 |
nM |
10.1038/s41467-023-40064-9 |
| Homo sapiens |
Vasopressin V1a receptor |
AC50 |
30000.0 |
nM |
10.1038/s41467-023-40064-9 |
| Homo sapiens |
Vasopressin V2 receptor |
AC50 |
30000.0 |
nM |
10.1038/s41467-023-40064-9 |
| Homo sapiens |
Vitamin D receptor |
Potency |
28183.8 |
nM |
None |
| Mus musculus |
B16 |
IC50 |
80000.0 |
nM |
10.1021/acs.jmedchem.1c00582 |
| Mus musculus |
Nuclear receptor ROR-gamma |
Potency |
35481.3 |
nM |
None |
| Oryctolagus cuniculus |
Endothelin receptor type A |
Inhibition |
22.54 |
% |
10.1016/j.bmcl.2011.05.034 |
| Oryctolagus cuniculus |
Oryctolagus cuniculus |
Kb |
130.0 |
nM |
10.1021/jm020289q |
| Rattus norvegicus |
Androgen Receptor |
AC50 |
30000.0 |
nM |
10.1038/s41467-023-40064-9 |
| Rattus norvegicus |
Bile salt export pump |
IC50 |
30600.0 |
nM |
10.1124/dmd.111.040758 |
| Rattus norvegicus |
Bile salt export pump |
Ki |
12000.0 |
nM |
10.1067/mcp.2001.114667 |
| Rattus norvegicus |
Cyclooxygenase-1 |
AC50 |
30000.0 |
nM |
10.1038/s41467-023-40064-9 |
| Rattus norvegicus |
Endothelin receptor |
BP increase |
7.0 |
% |
10.1021/jm9910425 |
| Rattus norvegicus |
Endothelin receptor |
BP increase |
1399.0 |
AUD30min |
10.1021/jm9910425 |
| Rattus norvegicus |
Endothelin receptor |
Selectivity |
53.0 |
None |
10.1021/jm030528p |
| Rattus norvegicus |
Endothelin receptor ET-A |
IC50 |
4.7 |
nM |
10.1016/j.bmc.2015.01.003 |
| Rattus norvegicus |
Endothelin receptor ET-A |
Kd |
39.81 |
nM |
10.1016/j.bmcl.2016.06.014 |
| Rattus norvegicus |
Endothelin receptor ET-A |
Kd |
50.12 |
nM |
10.1016/S0960-894X(97)00400-9 |
| Rattus norvegicus |
Endothelin receptor ET-A |
Kd |
72.44 |
nM |
10.1016/s0960-894x(02)01084-3 |
| Rattus norvegicus |
Endothelin receptor ET-A |
Ki |
6.5 |
nM |
10.1021/jm030528p |
| Rattus norvegicus |
Endothelin receptor ET-A |
pA2 |
nan |
None |
10.1016/S0960-894X(97)00400-9 |
| Rattus norvegicus |
Endothelin receptor ET-B |
IC50 |
95.0 |
nM |
10.1016/j.bmc.2015.01.003 |
| Rattus norvegicus |
Endothelin receptor ET-B |
Kd |
1584.89 |
nM |
10.1016/S0960-894X(97)00400-9 |
| Rattus norvegicus |
Endothelin receptor ET-B |
pA2 |
nan |
None |
10.1016/S0960-894X(97)00400-9 |
| Rattus norvegicus |
GABA receptor alpha-1 subunit |
AC50 |
10000.0 |
nM |
10.1038/s41467-023-40064-9 |
| Rattus norvegicus |
Glutamate (NMDA) receptor subunit zeta 1 |
AC50 |
10000.0 |
nM |
10.1038/s41467-023-40064-9 |
| Rattus norvegicus |
Liver |
IC50 |
100.0 |
nM |
10.1002/hep.27206 |
| Rattus norvegicus |
Liver microsome |
CLH |
37.0 |
microM/min/mg |
10.1021/acs.jmedchem.5b00258 |
| Rattus norvegicus |
Nuclear receptor subfamily 1 group I member 2 |
Activity |
nan |
None |
10.1124/dmd.110.035105 |
| Rattus norvegicus |
Rattus norvegicus |
ABC |
340.0 |
None |
10.1016/s0960-894x(02)01084-3 |
| Rattus norvegicus |
Rattus norvegicus |
Activity |
nan |
None |
10.1021/acs.jmedchem.9b00123 |
| Rattus norvegicus |
Rattus norvegicus |
Activity |
nan |
None |
10.1021/jm030528p |
| Rattus norvegicus |
Rattus norvegicus |
Activity |
nan |
None |
10.1021/jm3009103 |
| Rattus norvegicus |
Rattus norvegicus |
CL |
55.0 |
mL.min-1.kg-1 |
10.1021/jm991030j |
| Rattus norvegicus |
Rattus norvegicus |
Clearance |
1.3 |
ul min-1 |
10.1021/jm991030j |
| Rattus norvegicus |
Rattus norvegicus |
MPE |
7.0 |
mmHg |
10.1021/jm3009103 |
| Rattus norvegicus |
Rattus norvegicus |
MPE |
30.0 |
mmHg |
10.1021/jm3009103 |
| Rattus norvegicus |
Rattus norvegicus |
T1/2 |
4.0 |
hr |
10.1021/jm970101g |
| Rattus norvegicus |
Rattus norvegicus |
TIME |
15.0 |
hr |
10.1021/jm3009103 |
| Rattus norvegicus |
Rattus norvegicus |
TIME |
72.0 |
hr |
10.1021/jm3009103 |
| Rattus norvegicus |
Voltage-gated L-type calcium channel alpha-1C subunit |
AC50 |
10000.0 |
nM |
10.1038/s41467-023-40064-9 |
| Rattus norvegicus |
Voltage-gated N-type calcium channel alpha-1B subunit |
AC50 |
10000.0 |
nM |
10.1038/s41467-023-40064-9 |
| Severe acute respiratory syndrome coronavirus 2 |
Replicase polyprotein 1ab |
Inhibition |
4.397 |
% |
10.6019/CHEMBL4495564 |
| Severe acute respiratory syndrome coronavirus 2 |
Replicase polyprotein 1ab |
Inhibition |
12.14 |
% |
10.6019/CHEMBL4495564 |
| Severe acute respiratory syndrome coronavirus 2 |
SARS-CoV-2 |
Hit score |
0.2095 |
None |
10.1101/2020.04.21.054387 |
| Severe acute respiratory syndrome coronavirus 2 |
SARS-CoV-2 |
IC50 |
19952.62 |
nM |
10.6019/CHEMBL4651402 |
| Severe acute respiratory syndrome coronavirus 2 |
SARS-CoV-2 |
IC50 |
20000.0 |
nM |
10.6019/CHEMBL4651402 |
| Severe acute respiratory syndrome coronavirus 2 |
SARS-CoV-2 |
Inhibition |
-0.48 |
% |
10.21203/rs.3.rs-23951/v1 |
| Severe acute respiratory syndrome coronavirus 2 |
SARS-CoV-2 |
Inhibition |
0.24 |
% |
10.6019/CHEMBL4495565 |
| Severe acute respiratory syndrome coronavirus 2 |
SARS-CoV-2 |
Inhibition |
0.51 |
% |
10.6019/CHEMBL4495565 |
| Severe acute respiratory syndrome coronavirus 2 |
SARS-CoV-2 |
Inhibition index |
0.6519 |
None |
10.1101/2020.04.03.023846 |
| Sus scrofa |
Endothelin receptor ET-A |
IC50 |
7.5 |
nM |
10.1016/s0960-894x(01)00682-5 |
| None |
ADMET |
CL |
2.1 |
mL.min-1.kg-1 |
10.1124/dmd.108.020479 |
| None |
ADMET |
CL |
2.2 |
mL.min-1.kg-1 |
10.1021/acs.jmedchem.0c01033 |
| None |
ADMET |
CL |
4.79 |
uL.min-1.(10^6cells)-1 |
10.6019/CHEMBL3301361 |
| None |
ADMET |
CL |
15.14 |
mL.min-1.g-1 |
10.6019/CHEMBL3301361 |
| None |
ADMET |
CL |
15.9 |
mL.min-1.kg-1 |
10.1021/acs.jmedchem.0c01033 |
| None |
ADMET |
CL |
16.0 |
mL.min-1.kg-1 |
10.1021/acs.jmedchem.0c01033 |
| None |
ADMET |
CL |
33.1 |
mL.min-1.kg-1 |
10.1021/acs.jmedchem.0c01033 |
| None |
ADMET |
Drug metabolism |
nan |
None |
10.1016/j.ejmech.2016.06.006 |
| None |
ADMET |
F |
30.0 |
% |
10.1021/jm970101g |
| None |
ADMET |
Fu |
0.000121 |
None |
10.1021/acs.jmedchem.0c01033 |
| None |
ADMET |
Fu |
0.000285 |
None |
10.1021/acs.jmedchem.0c01033 |
| None |
ADMET |
Fu |
0.000422 |
None |
10.1021/acs.jmedchem.0c01033 |
| None |
ADMET |
MRT |
2.3 |
hr |
10.1124/dmd.108.020479 |
| None |
ADMET |
Papp |
7.4 |
10^-6 cm/s |
10.1021/acs.jmedchem.0c01033 |
| None |
ADMET |
PPB |
98.7 |
% |
10.6019/CHEMBL3301361 |
| None |
ADMET |
PPB |
98.78 |
% |
10.6019/CHEMBL3301361 |
| None |
ADMET |
Ratio |
0.668 |
None |
10.1021/acs.jmedchem.0c01033 |
| None |
ADMET |
Ratio |
0.69 |
None |
10.1021/acs.jmedchem.0c01033 |
| None |
ADMET |
Ratio |
1.19 |
None |
10.1021/acs.jmedchem.0c01033 |
| None |
ADMET |
Stability |
91.6 |
% |
10.1016/j.ejmech.2016.06.006 |
| None |
ADMET |
T1/2 |
4.1 |
hr |
10.1124/dmd.108.020479 |
| None |
ADMET |
Vdss |
0.29 |
L.kg-1 |
10.1124/dmd.108.020479 |
| None |
Hepatotoxicity |
Hepatotoxicity |
nan |
None |
10.1021/tx1000865 |
| None |
Hepatotoxicity |
Hepatotoxicity |
nan |
None |
10.1021/tx900326k |
| None |
Hepatotoxicity |
Hepatotoxicity |
nan |
None |
10.1124/dmd.110.035113 |
| None |
Hepatotoxicity |
HepSE_bilirubinemia |
0.0 |
None |
10.1371/journal.pcbi.1002310 |
| None |
Hepatotoxicity |
HepSE_cholecystitis |
0.0 |
None |
10.1371/journal.pcbi.1002310 |
| None |
Hepatotoxicity |
HepSE_cholelithiasis |
0.0 |
None |
10.1371/journal.pcbi.1002310 |
| None |
Hepatotoxicity |
HepSE_cirrhosis |
1.0 |
None |
10.1371/journal.pcbi.1002310 |
| None |
Hepatotoxicity |
HepSE_Combined Scores |
4.0 |
None |
10.1371/journal.pcbi.1002310 |
| None |
Hepatotoxicity |
HepSE_elevated liver function tests |
0.0 |
None |
10.1371/journal.pcbi.1002310 |
| None |
Hepatotoxicity |
HepSE_hepatic failure |
1.0 |
None |
10.1371/journal.pcbi.1002310 |
| None |
Hepatotoxicity |
HepSE_hepatic necrosis |
0.0 |
None |
10.1371/journal.pcbi.1002310 |
| None |
Hepatotoxicity |
HepSE_hepatitis |
1.0 |
None |
10.1371/journal.pcbi.1002310 |
| None |
Hepatotoxicity |
HepSE_hepatomegaly |
0.0 |
None |
10.1371/journal.pcbi.1002310 |
| None |
Hepatotoxicity |
HepSE_jaundice |
1.0 |
None |
10.1371/journal.pcbi.1002310 |
| None |
Hepatotoxicity |
HepSE_liver disease |
0.0 |
None |
10.1371/journal.pcbi.1002310 |
| None |
Hepatotoxicity |
HepSE_liver fatty |
0.0 |
None |
10.1371/journal.pcbi.1002310 |
| None |
Hepatotoxicity |
HepSE_liver function tests abnormal |
0.0 |
None |
10.1371/journal.pcbi.1002310 |
| None |
Hepatotoxicity |
LTKB_BD DILI severity score |
7.0 |
None |
10.1016/j.drudis.2011.05.007 |
| None |
NON-PROTEIN TARGET |
Fu |
0.037 |
None |
10.1124/dmd.108.020479 |
| None |
NON-PROTEIN TARGET |
Hepatotoxicity (acute) |
5.3 |
% |
10.1016/s0399-8320(04)95062-2 |
| None |
NON-PROTEIN TARGET |
Hepatotoxicity (animal toxicity known) |
nan |
None |
10.1016/s0399-8320(04)95062-2 |
| None |
NON-PROTEIN TARGET |
Hepatotoxicity (benign tumour) |
0.0 |
None |
10.1016/s0399-8320(04)95062-2 |
| None |
NON-PROTEIN TARGET |
Hepatotoxicity (granulomatous hepatitis) |
0.0 |
None |
10.1016/s0399-8320(04)95062-2 |
| None |
NON-PROTEIN TARGET |
Hepatotoxicity (mechanism) |
nan |
None |
10.1016/s0399-8320(04)95062-2 |
| None |
NON-PROTEIN TARGET |
Hepatotoxicity (moderate) |
12.0 |
None |
10.1016/s0399-8320(04)95062-2 |
| None |
NON-PROTEIN TARGET |
Hepatotoxicity (moderate) |
15.0 |
% |
10.1016/s0399-8320(04)95062-2 |
| None |
NON-PROTEIN TARGET |
Hepatotoxicity (time to onset) |
nan |
None |
10.1016/s0399-8320(04)95062-2 |
| None |
NON-PROTEIN TARGET |
IC50 |
195900.0 |
nM |
10.1016/j.ejmech.2016.06.006 |
| None |
No relevant target |
CLogP |
nan |
None |
10.1021/jm020289q |
| None |
No relevant target |
LogD |
1.2 |
None |
10.1021/acs.jmedchem.0c01033 |
| None |
No relevant target |
LogD7.4 |
1.03 |
None |
10.6019/CHEMBL3301361 |
| None |
No relevant target |
pKa |
4.9 |
None |
10.1021/acs.jmedchem.0c01033 |
| None |
No relevant target |
pKa |
8.36 |
None |
10.1124/dmd.112.050278 |
| None |
No relevant target |
Retention_time |
5.1 |
min |
10.1016/j.ejmech.2016.06.006 |
| None |
Unchecked |
Ac50 |
1.413 |
uM |
None |
| None |
Unchecked |
Ac50 |
1.778 |
uM |
None |
| None |
Unchecked |
Ac50 |
2.512 |
uM |
None |
| None |
Unchecked |
Ac50 |
3.548 |
uM |
None |
| None |
Unchecked |
Ac50 |
5.623 |
uM |
None |
| None |
Unchecked |
AC50 |
1412.5 |
nM |
None |
| None |
Unchecked |
AC50 |
1778.3 |
nM |
None |
| None |
Unchecked |
AC50 |
2511.9 |
nM |
None |
| None |
Unchecked |
AC50 |
3550.0 |
nM |
None |
| None |
Unchecked |
AC50 |
5623.4 |
nM |
None |
| None |
Unchecked |
EC50 |
530.0 |
nM |
10.1016/j.bmc.2017.07.002 |
| None |
Unchecked |
Hepatotoxicity (acute) |
5.0 |
None |
10.1016/s0399-8320(04)95062-2 |
| None |
Unchecked |
Hepatotoxicity (association with vascular disease) |
0.0 |
None |
10.1016/s0399-8320(04)95062-2 |
| None |
Unchecked |
Hepatotoxicity (choleostasis) |
1.0 |
None |
10.1016/s0399-8320(04)95062-2 |
| None |
Unchecked |
Hepatotoxicity (chronic liver disease) |
0.0 |
None |
10.1016/s0399-8320(04)95062-2 |
| None |
Unchecked |
Hepatotoxicity (cirrhosis) |
0.0 |
None |
10.1016/s0399-8320(04)95062-2 |
| None |
Unchecked |
Hepatotoxicity (comment) |
nan |
None |
10.1016/s0399-8320(04)95062-2 |
| None |
Unchecked |
Hepatotoxicity (cytolytic) |
4.0 |
None |
10.1016/s0399-8320(04)95062-2 |
| None |
Unchecked |
Hepatotoxicity (malignant tumour) |
0.0 |
None |
10.1016/s0399-8320(04)95062-2 |
| None |
Unchecked |
Hepatotoxicity (severe hepatitis) |
0.0 |
None |
10.1016/s0399-8320(04)95062-2 |
| None |
Unchecked |
Hepatotoxicity (steatosis) |
0.0 |
None |
10.1016/s0399-8320(04)95062-2 |
| None |
Unchecked |
Hepatotoxicity (successful reintroduction) |
nan |
None |
10.1016/s0399-8320(04)95062-2 |
| None |
Unchecked |
Potency |
2.6 |
nM |
None |
| None |
Unchecked |
Ratio |
0.032 |
None |
10.1093/toxsci/kft176 |
| None |
Unchecked |
Ratio |
0.059 |
None |
10.1093/toxsci/kft176 |
| None |
Unchecked |
Ratio |
0.061 |
None |
10.1093/toxsci/kft176 |
| None |
Unchecked |
Ratio |
53.0 |
None |
10.1021/jm970101g |
| None |
Unchecked |
Ratio IC50 |
20.0 |
None |
10.1016/j.bmc.2015.01.003 |